http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
FAMILY PLANNING OPINION LEADERSHIP IN KOREA : 1971
PALMORE,JAMES A,BUCHMEIER,FRANCIS X,FURLONG,MICHAE J,PARK,HAN INSOOK,SOUDER,LAURA M 연세대학교 동서문제연구소 1975 東西硏究 JOURNAL OF EAST AND WEST STUDIES Vol.4 No.2
In effect, what characterized Korean family planning opinion leaders in 1971 was a rather rational and democratic model. Those who had had actually tried methods, discussed them, and knew a lot about them played the leadership role more than others. Place of residence, education, and other such variables mattered relatively little unless the woman had the credibility imparted by actual use and the knowledge imparted by use or discussions with family planning professionals.
Dong Athena,Pan Xiaoqing,Lin Chien-Wei,Huang Yi-Wen,Krause Hayden,Pan Pan,Baim Arielle,Thomas Michael J,Chen Xiao,Yu Jianhua,Michaelis Laura,Liu Pengyuan,Wang Li-Shu,Atallah Ehab 대한암예방학회 2022 Journal of cancer prevention Vol.27 No.2
Myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are bone marrow disorders characterized by cytopenias and progression to acute myeloid leukemia. Hypomethylating agents (HMAs) are Food and Drug Administration-approved therapies for MDS and MDS/MPN patients. HMAs have improved patients’ survival and quality of life when compared with other therapies. Although HMAs are effective in MDS and MDS/MPN patients, they are associated with significant toxicities that place a large burden on patients. Our goal is to develop a safer and more effective HMA from natural products. We previously reported that black raspberries (BRBs) have hypomethylating effects in the colon, blood, spleen, and bone marrow of mice. In addition, BRBs exert hypomethylating effects in patients with colorectal cancer and familial adenomatous polyposis. In the current study, we conducted a pilot clinical trial to evaluate the hypomethylating effects of BRBs in patients with low-risk MDS or MDS/MPN. Peripheral blood mononuclear cells (PBMCs) were isolated before and after three months of BRB intervention. CD45+ cells were isolated from PBMCs for methylation analysis using a reduced-representation bisulfite sequencing assay. Each patient served as their own matched control, with their measurements assessed before intervention providing a baseline for post-intervention results. Clinically, our data showed that BRBs were well-tolerated with no side effects. When methylation data was combined, BRBs significantly affected methylation levels of 477 promoter regions. Pathway analysis suggests that BRB-induced intragenic hypomethylation drives leukocyte differentiation. A randomized, placebo-controlled clinical trial of BRB use in low-risk MDS or MDS/ MPN patients is warranted.